Oxford Asset Management’s Spero Therapeutics SPRO Stock Holding History

Oxford Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-58,868	Closed	-$566K	–	1151
2019 Q4	$566K	Sell	58,868 -15,940	-21%	-$172K	0.02%	1180
2019 Q3	$793K	Sell	74,808 -4,285	-5%	-$45.2K	0.02%	1059
2019 Q2	$910K	Buy	79,093 +11,377	+17%	+$137K	0.02%	1021
2019 Q1	$867K	Buy	67,716 +19,334	+40%	+$205K	0.02%	1000
2018 Q4	$298K	Buy	48,382 +34,666	+253%	+$281K	0.01%	1406
2018 Q3	$158K	Buy	+13,716	New	+$159K	﹤0.01%	1622

Other funds holding SPRO

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Oxford Asset Management's SPRO Position: Q1 2020 in Review

Oxford Asset Management sold out of Spero Therapeutics (SPRO) in Q1 2020, closing a stake of 58,868 shares — an estimated $566K sold.

Oxford Asset Management first reported a position in SPRO in Q3 2018 and held it in 6 quarters. The position peaked at $910K in Q2 2019. 60 funds tracked by Wall St. Rank hold SPRO as of Q1 2020.

Oxford Asset Management reported no remaining Spero Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 58,868 Spero Therapeutics shares in Q1 2020, an estimated $566K.
Oxford Asset Management first reported a position in Spero Therapeutics in Q3 2018 and held it in 6 quarters.
Oxford Asset Management's Spero Therapeutics position peaked at $910K in Q2 2019.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.